论文部分内容阅读
目的探究口服与静脉滴注阿奇霉素治疗小儿支原体肺炎的疗效。方法 70例小儿支原体肺炎患儿,随机分成观察组和对照组,各35例。观察组口服阿奇霉素干混悬剂(商品名:希舒美),对照组静脉滴注乳糖酸阿奇霉素,比较两组患儿治疗后的临床表现。结果治疗后,观察组(91.43%)与对照组(94.29%)的有效率差异无统计学意义(P>0.05);观察组咳嗽明显减轻时间(5.4±1.5)d、发热消退的时间(4.0±1.0)d与对照组的时间(5.2±1.2)d、(3.4±0.8)d,差异均无统计学意义(P>0.05)。观察组患儿的不良反应(2.86%)明显低于对照组的(14.28%),差异具有统计学意义(P<0.05)。结论口服与静脉使用阿奇霉素治疗小儿支原体肺炎的临床效果无明显差异,口服用药经济,不良反应少,患儿易接受,值得广泛使用。
Objective To investigate the efficacy of oral and intravenous azithromycin in children with mycoplasma pneumonia. Methods Seventy children with mycoplasma pneumonia were randomly divided into observation group and control group with 35 cases each. The observation group was given azithromycin as suspension (brand name: Xishuangmei), and the control group received intravenous infusion of azithromycin lactobionate. The clinical manifestations of the two groups of children after treatment were compared. Results After treatment, there was no significant difference in the effective rate between the observation group (91.43%) and the control group (94.29%) (P> 0.05). The cough was relieved in the observation group (5.4 ± 1.5) d and the fever subsided time ± 1.0) d and the control group (5.2 ± 1.2) d, (3.4 ± 0.8) d, the difference was not statistically significant (P> 0.05). Adverse reactions in the observation group (2.86%) were significantly lower than those in the control group (14.28%), the difference was statistically significant (P <0.05). Conclusion Oral and intravenous azithromycin treatment of children with mycoplasma pneumonia no significant difference in clinical effect, oral medication economy, fewer adverse reactions, children are easy to accept, it is widely used.